Zealand Pharma, Boehringer collaborate to develop type-2 diabetes, obesity drugs
Boehringer obtains development and commercialisation rights to ZP2929 – Zealand Pharma’s glucagon/GLP-1 dual agonist drug candidate. Under the agreement, Zealand Pharma will be responsible for conducting the first
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.